Vita 34 AG, DE000A0BL849

Vita 34 AG, DE000A0BL849

13.06.2017 - 18:34:39

Vita 34 AG decides on a capital increase of around 10%

NOT FOR DISTRIBUTION, PUBLICATION OR DISCLOSURE IN OR WITHIN THE US, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION IS UNLAWFUL. PLEASE NOTE THE IMPORTANT NOTICES AT THE END OF THIS COMMUNICATION.

Vita 34 AG decides on a capital increase of around 10%

- Strategic investor MK Beleggingsmaatschappij Venlo B.V. (Netherlands) to acquire a stake in Vita 34

- Issue Price of EUR 6.62

Leipzig, June 13, 2017 - The Management Board of Vita 34 AG in Leipzig (ISIN: DE000A0BL849, WKN: A0BL84) (the "Company"), with approval of the Supervisory Board, has decided to increase the Company's share capital by approximately 10 percent against cash contributions (the "Capital Increase"), partially using Authorized Capital 2014.

The statutory subscription right of current shareholders of Vita 34 AG has been excluded as subscription and acquisition are authorized only to MK Beleggingsmaatschappij Venlo B.V., Venlo (Netherlands) ("MKBV"). MKBV is a strategic investor focusing on the medical technology and pharmaceuticals industry.

The Company's share capital is to be increased by EUR 302,649.00 from its current level of EUR 3,026,500.00 to EUR 3,329,149.00 by issuing 302,649 new no-par value shares with each single share's nominal portion of the share capital of the Company at EUR 1.00 ("New Shares"). The New Shares are to be issued at a price of EUR 6.62 per New Share and are entitled to participate in profit from January 1, 2017.

The New Shares are to be admitted to trading without a prospectus on the Regulated Market of the Frankfurt Stock Exchange with further admission requirements (Prime Standard).

The gross proceeds of approximately EUR 2 million from this private placement will be used to finance parts of the acquisition of the Seracell AG, Berlin.

On April 20, 2017, a purchase agreement was closed under suspensive condition and executed with the positive due diligence on May 26, 2017. Additionally, the purchase price of EUR 14 million will be financed by an intended rights offering of up to EUR 5 million and a bank financing. The completion of the acquisition is planned in the fourth quarter 2017.

Notifying person: Dr. Wolfgang Knirsch (Chairman of the Management Board)

Additional information:

ISIN: DE000A0BL849 WKN: A0BL84 Ticker symbol: V3V Market segment: Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

Vita 34 AG Deutscher Platz 5 04103 Leipzig Germany

Information and Explanation of the Issuer to this News:

IMPORTANT NOTICE:

This publication neither constitutes an offer to sell nor an invitation to submit an offer to purchase or subscribe for securities.

This publication may not be released, published or distributed in the United States of America, Australia, Japan or Canada. This publication neither constitutes an offer to sell nor an invitation to submit an offer to purchase or subscribe for securities (the 'Shares') in Vita 34 AG within the United States of America, Germany or any other state. Shares in Vita 34 AG may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 'Securities Act'). Shares in Vita 34 AG are not and will not be registered in accordance with the provisions of the U.S. Securities Act.

As far as this document contains forward-looking statements these statements do not constitute facts and may be identified by words such as 'will', 'expect', 'believe', 'estimate', 'intend', 'aim', 'assume' or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of Vita 34 AG and persons acting in conjunction with Vita 34 AG. Any forward-looking statements contained in this document are based on current plans, estimates and projections which Vita 34 AG and persons acting in conjunction with Vita 34 AG have made to the best of their knowledge, but which do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by Vita 34 AG or persons acting in conjunction with Vita 34 AG. It should be kept in mind that the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements.

13-Jun-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig

Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: ir@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of Announcement DGAP News Service

582785  13-Jun-2017 CET/CEST

@ dgap.de